Skip to main content

Advertisement

SpringerLink
Log in

Reactivation of Occult HBV Infection in Patients Cured of HCV With Direct-Acting Antivirals

  • Hepatitis C (J Raybould, Section Editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Opinion statement

The era of hepatitis C virus (HCV) treatment with direct-acting antiviral (DAA) therapy has remarkably improved liver-related morbidity and overall mortality with patients achieving rapid and sustained clearance of HCV infection. The initial DAA clinical trials excluded patients with hepatitis B virus (HBV) co-infection, and thus potential complications were unforeseen until case reports of HBV reactivation associated with DAA therapy began to emerge. A recent United States Food and Drug Administration (FDA) drug safety communication has brought public attention to the issue of HBV reactivation in patients treated with DAA for HCV co-infection. Reactivation of HBV is well known to occur with a variety of immune-suppressive therapies notably in the context of cancer, rheumatologic treatments, and organ transplantation. While HBV reactivation in the setting of DAA therapy remains rare, the severity of hepatitis can be profound and deadly. Early recognition and treatment are keys to improving patient outcomes. Therefore, it is currently recommended to screen all patients for current or prior HBV infection prior to starting DAA therapy. If either hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc) is positive, HBV DNA should be obtained. With active viremia, prophylactic therapy should be started with DAA treatment with an agent with a high barrier for resistance. If there is no evidence of active viremia, the risks and benefits of prophylactic therapy should be weighed. Those with positive HBsAg should consider prophylactic therapy. Those with an isolated anti-HBc in the absence of HBsAg have an option of monitoring their liver enzymes, HBV DNA, and HBsAg at regular intervals during DAA therapy. If prophylactic HBV therapy is initiated, it should be continued for at least 3 months after DAA therapy is complete. After this period, the risks and benefits of continuing their HBV therapy should be re-addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Sagnelli C, Macera M, Pisaturo M, et al. Occult HBV infection in the oncohematological setting. Infection. 2016;44:575–82.

    Article  CAS  PubMed  Google Scholar 

  2. Tyson GL, Kramer JR, Duan Z, et al. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013;58:538–45.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.

    Article  CAS  PubMed  Google Scholar 

  4. • Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomized study. Lancet. 2014;384:1756–65. Demonstrated that the combination of simeprevir and sofosbuvir led to a high rate of SVR12 in a patient population traditionally felt difficult to cure

    Article  CAS  PubMed  Google Scholar 

  5. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis. https://www.fda.gov/Drugs/DrugSafety/ucm522932.htm. Accessed 10 May 2017.

  6. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–52.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol. 1998;36:2084–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004;126:1024–9.

    Article  PubMed  Google Scholar 

  9. Biliotti E, Kondili LA, Furlan C, et al. Acute hepatitis B in patients with or without underlying chronic HCV infection. J Inf Secur. 2008;57:152–7.

    CAS  Google Scholar 

  10. Balagopal A, Thio CL. Another call to cure hepatitis B. Clin Infect Dis. 2015;61:1307–9.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Liu JY, Sheng YJ, Hu HD, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J. 2012;9:186.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with A-interferon and ribavirin. J Gastroenterol. 2003;38:796–800.

    Article  CAS  PubMed  Google Scholar 

  13. Fabbri G, Mastrorosa I, Vergori A, et al. Reactivation of occult HBV infection in an HIV/HCV co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. BMC Infect Dis. 2017;17:182.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simepravir. Clin Infect Dis. 2015;61:1304–6.

    Article  CAS  PubMed  Google Scholar 

  15. • Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017;66:27–36. A large cohort study of veterans infected with chronic hepatitis B infection who were treated with DAA therapy which reports on the prevalence and characteristics of HBV reactivation

    Article  CAS  PubMed  Google Scholar 

  16. Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66:13–26.

    Article  CAS  PubMed  Google Scholar 

  17. De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reaction of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27–30.

    Article  PubMed  Google Scholar 

  18. Lepelletier C, Salmona M, Bercot B, et al. First description of past hepatitis B virus infection acute reactivation occurring in a human immunodeficiency virus infected patient as manifestation of immune reconstitution inflammatory syndrome. J Infect Chemother. 2016;22:490–4.

    Article  PubMed  Google Scholar 

  19. AASLD-IDSA: Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. 10 May 2017. Combined hepatology and infectious diseases societal guidelines on the evaluation and management of hepatitis C infection.

  20. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.

    Article  Google Scholar 

  21. Launay O, Masurel J, Servant-Delmas A, et al. High levels of serum hepatitis B virus DNA in patients with ‘anti-HBc alone’: role of HBsAg mutants. J Viral Hepat. 2011;18:721–9.

    Article  CAS  PubMed  Google Scholar 

  22. Terrault NA, Bzowej NH, Chang K-M, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Digestive Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA

    Karen Ma MD & Susanne Shokoohi MD

  2. Section of Hepatology, Division of Digestive Diseases, Department of Internal Medicine, Rush University Medical Center, 1725 W. Harrison Street, Suite 319, Chicago, IL, 60612, USA

    Nancy Reau MD

Authors
  1. Karen Ma MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Shokoohi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nancy Reau MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nancy Reau MD.

Ethics declarations

Conflict of interest

Karen Ma has no relevant disclosures to report.

Susanne Shokoohi has no relevant disclosures to report.

Nancy Reau: Consultation: AbbVie, Abbott, Gilead, Merck; Research funding: AbbVie.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hepatitis C

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, K., Shokoohi, S. & Reau, N. Reactivation of Occult HBV Infection in Patients Cured of HCV With Direct-Acting Antivirals. Curr Treat Options Infect Dis 9, 380–388 (2017). https://doi.org/10.1007/s40506-017-0134-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-017-0134-8

Keywords

Search

Navigation